The CTLA-4 ligand, CD86 (CD86 mRNA), was significantly elevated in tumours from Trp53(R245W/R245W) and Trp53(−/−) aged 12 weeks, relative to the wt Trp53 controls (Fig. 5d). Here, CD86 is linked to neoplasm.